Escherichia coli Infections R&D Pipeline Analysis Report, Q4 2020
Escherichia coli Infections Pipeline Overview
The Q4 Escherichia coli Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Escherichia coli Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Escherichia coli Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Escherichia coli Infections disease overview, Escherichia coli Infections types, Escherichia coli Infections symptoms, causes, and FDA/EMA approved treatment options.
Escherichia coli Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Escherichia coli Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Escherichia coli Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 38 companies. Business profiles and contact details of the companies actively perusing Escherichia coli Infections pipeline are assessed.
Escherichia coli Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Escherichia coli Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Escherichia coli Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Escherichia coli Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Escherichia coli Infections Pipeline Market News and Developments during 2020
The Escherichia coli Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Escherichia coli Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Escherichia coli Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Escherichia coli Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Escherichia coli Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Escherichia coli Infections disease overview, Escherichia coli Infections types, Escherichia coli Infections symptoms, causes, and FDA/EMA approved treatment options.
Escherichia coli Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Escherichia coli Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Escherichia coli Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 38 companies. Business profiles and contact details of the companies actively perusing Escherichia coli Infections pipeline are assessed.
Escherichia coli Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Escherichia coli Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Escherichia coli Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Escherichia coli Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Escherichia coli Infections Pipeline Market News and Developments during 2020
The Escherichia coli Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Escherichia coli Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Escherichia coli Infections pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 38 companies are included including ABAC Therapeutics SA, AstraZeneca Plc, BB100 LLC, Biomendics LLC, Bugworks Research India Pvt Ltd, ContraFect Corp, Debiopharm International SA, Eligochem Ltd, EnBiotix Inc, EveliQure Biotechnologies GmbH, F. Hoffmann-La Roche Ltd, Forge Therapeutics Inc, GlyProVac ApS, Immuron Ltd, Johnson & Johnson, Kyorin Pharmaceutical Co Ltd, Linnaeus Bioscience Inc, Meiji Seika Pharma Co Ltd, Melinta Therapeutics Inc, Merck & Co Inc, Microbiotix Inc, Navigen Inc, Neoculi Pty Ltd, Northern Antibiotics Oy, Nosopharm SAS, Ostrich Pharma USA Inc, Oxford Drug Design Ltd, Paratek Pharmaceuticals Inc, Phico Therapeutics Ltd, Procarta Biosystems Ltd, Protein Potential LLC, Pylum Biosciences Inc, Recce Pharmaceuticals Ltd, Sealife PHARMA GMBH, Soligenix Inc, Spero Therapeutics Inc, Syntiron LLC, Venus Medicine Research Center,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Escherichia coli Infections pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. ESCHERICHIA COLI INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Escherichia coli Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Escherichia coli Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Escherichia coli Infections pipeline
2.5 Active Companies Developing Escherichia coli Infections pipeline
3. ESCHERICHIA COLI INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. ESCHERICHIA COLI INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 ABAC Therapeutics SA
AstraZeneca Plc
BB100 LLC
Biomendics LLC
Bugworks Research India Pvt Ltd
ContraFect Corp
Debiopharm International SA
Eligochem Ltd
EnBiotix Inc
EveliQure Biotechnologies GmbH
F. Hoffmann-La Roche Ltd
Forge Therapeutics Inc
GlyProVac ApS
Immuron Ltd
Johnson & Johnson
Kyorin Pharmaceutical Co Ltd
Linnaeus Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Navigen Inc
Neoculi Pty Ltd
Northern Antibiotics Oy
Nosopharm SAS
Ostrich Pharma USA Inc
Oxford Drug Design Ltd
Paratek Pharmaceuticals Inc
Phico Therapeutics Ltd
Procarta Biosystems Ltd
Protein Potential LLC
Pylum Biosciences Inc
Recce Pharmaceuticals Ltd
Sealife PHARMA GMBH
Soligenix Inc
Spero Therapeutics Inc
Syntiron LLC
Venus Medicine Research Center
5. ESCHERICHIA COLI INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. ESCHERICHIA COLI INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. ESCHERICHIA COLI INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Escherichia coli Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Escherichia coli Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Escherichia coli Infections pipeline
2.5 Active Companies Developing Escherichia coli Infections pipeline
3. ESCHERICHIA COLI INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. ESCHERICHIA COLI INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 ABAC Therapeutics SA
AstraZeneca Plc
BB100 LLC
Biomendics LLC
Bugworks Research India Pvt Ltd
ContraFect Corp
Debiopharm International SA
Eligochem Ltd
EnBiotix Inc
EveliQure Biotechnologies GmbH
F. Hoffmann-La Roche Ltd
Forge Therapeutics Inc
GlyProVac ApS
Immuron Ltd
Johnson & Johnson
Kyorin Pharmaceutical Co Ltd
Linnaeus Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Navigen Inc
Neoculi Pty Ltd
Northern Antibiotics Oy
Nosopharm SAS
Ostrich Pharma USA Inc
Oxford Drug Design Ltd
Paratek Pharmaceuticals Inc
Phico Therapeutics Ltd
Procarta Biosystems Ltd
Protein Potential LLC
Pylum Biosciences Inc
Recce Pharmaceuticals Ltd
Sealife PHARMA GMBH
Soligenix Inc
Spero Therapeutics Inc
Syntiron LLC
Venus Medicine Research Center
5. ESCHERICHIA COLI INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. ESCHERICHIA COLI INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
